Trials / Not Yet Recruiting
Not Yet RecruitingNCT06422624
A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects
An Open Label, Single Dose, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Semaglutide Extended-release Injectable Suspension in Normal Healthy, Adult, Human Study Participants Under Fasting Condition
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (estimated)
- Sponsor
- Bostal Drug Delivery Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the trail is to evaluate the safety, tolerability and pharmacokinetics of a single escalated doses of semaglutide extended-release injectable suspension in healthy adult, human study participants under fasting condition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide Extended-release for Injectable Suspension, 1 mg | Singel-dose; Subcutaneous |
| DRUG | Semaglutide Extended-release for Injectable Suspension, 4 mg | Singel-dose; Subcutaneous |
| DRUG | Semaglutide Extended-release for Injectable Suspension, 8 mg | Singel-dose; Subcutaneous |
Timeline
- Start date
- 2024-08-01
- Primary completion
- 2024-11-01
- Completion
- 2024-11-01
- First posted
- 2024-05-21
- Last updated
- 2024-05-22
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06422624. Inclusion in this directory is not an endorsement.